GSK (GSK) said Monday China's National Medical Products Administration has approved Blenrep in combination with bortezomib and dexamethasone to treat certain relapsed or refractory multiple myeloma patients.
The approval covers adults with relapsed or refractory multiple myeloma who have received at least one prior line of therapy.
Multiple myeloma is a type of blood cancer.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.